The President’s proposal, while only a framework for Congress’ consideration, establishes the priorities of the Administration. NCHC is concerned that the priorities of the Administration do not serve public health and do not align with the mission of the Coalition. […]
National Coalition Expresses Disappointment in 2019 Year-End Package, “Surprise Billing” and Drug Prices Missing
Although we applaud the inclusion of CREATES Act in the final year-end spending package, which will help provide a boost to the generic drugs market, the end of the year package lacks any significant changes to drug policy that would protect Americans from the most expensive drugs. Americans have consistently indicated that high and increasing drug prices are the top concern, across both Democrats and Republicans. […]
Multi-stakeholder Coalition Applauds Legislation to Provide Affordable Health Care to All Americans
Washington, DC – Yesterday, Speaker Nancy Pelosi (D-CA), Majority Leader Steny Hoyer (D-MD), Energy & Commerce Committee Chairman Frank Pallone Jr. (D-NJ), Ways & Means Committee Chairman Richard Neal (D-MA), and Education & Labor Committee Chairman Bobby Scott (D-VA) released a joint statement announcing that H.R. 3, the Lower Drug Costs Now Act, will come to a floor vote next week. The National Coalition on Health Care supports H.R. 3 to lower prescription drug prices and urges its swift passage to the U.S. Senate. […]
National Coalition on Health Care Announces Strategic Partnership to Advance Goal of Affordable Health Care in the U.S.
Today, the National Coalition on Health Care (NCHC), an alliance of national health care provider, purchaser, labor, payer and consumer organizations, announced a new strategic partnership with Healthsperien, LLC, a leading Washington, D.C.-based health policy consulting firm. […]
John Rother’s Orphan Drug Presentation
On April 10th, NCHC President & CEO John Rother presented at the World Orphan Drug Congress 2019 Conference & Expo to discuss potential policy options to address the rising cost of drugs. Mr. Rother discussed proposals from the FDA, HHS, and Congress. Mr. Rother also identified 4 feasible options to address drug affordability. The slides […]
- 1
- 2
- 3
- …
- 29
- Next Page »